Temasek-Backed Biotech Firm Innovent Seeks To Raise Up To $500M In HK IPO

Chinese biotech Innovent Biologics, Inc., backed by Singapore’s Temasek Holdings, is seeking to raise US$400 million to US$500 million in an initial public (IPO) offering in Hong Kong.

China Money Network

Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Want to read this important story?

Access Over 11,000 stories and data posts over the past 8 years!

Register Now

Already have an account or paid subscription? Log in